Göran Tornling

Publications
CV
Public outreach and news

Articles

Article: RHEUMATOLOGY. 2025;64(2):704-713
A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's
Tornling G; Edenius C; Pauling JD; Denton CP; Olsson A; Kowalski J; Murray A; Anderson M; Bhat S; Del Galdo F; Hall F; Korkosz M; Krasowska D; Olas J; Smith V; van Laar JM; Vonk MC; Wojteczek A; Herrick AL
Article: WORLD ALLERGY ORGANIZATION JOURNAL. 2024;17(4):100896
Disease burden and unmet need for acute allergic reactions - A patient perspective
Andersson E; Lofvendahl S; Olofsson S; Wahlberg K; Bjermer L; Tornling G; Janson C; Hjelmgren J
Article: JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH. 2024;11(1):157-165
Treatment Preferences for Acute Allergic Reactions: A Discrete Choice Experiment
Lofvendahl S; Andersson E; Olofsson S; Wahlberg K; Bjermer L; Tornling G; Hjelmgren J
Journal article: VALUE IN HEALTH. 2023;26(12):s200-s201
EE760 Using Discrete Choice Experiment to Elicit Treatment Preferences for Acute Allergic Reactions in Sweden: The Case of Patients with Swallowing Problems
Löfvendahl S; Andersson E; Tornling G; Olofsson S; Hjelmgren J
Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023;24(8):7478
Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats
Tornling G; Batta R; Salvail D; Raud J; Denton CP
Article: RHEUMATOLOGY. 2023;62(2):824-828
A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's
Herrick AL; Batta R; Overbeck K; Raud J; Manning J; Murray A; Dinsdale G; Tornling G
Journal article: EUROPEAN HEART JOURNAL. 2022;43(Supplement_2):ehac544.3044
Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19
Batta R; Tornling G; Rosendahl E; Bengtsson T; Raud J
Journal article: RHEUMATOLOGY. 2022;61(Supplement_1):keac132.006
OA07 A Phase 2 randomised placebo-controlled trial investigating the effect of the angiotensin II type 2 receptor agonist C21 on cold-induced vasoconstriction in patients with Raynaud's phenomenon secondary to systemic sclerosis
Herrick AL; Batta R; Overbeck K; Raud J; Manning J; Dinsdale G; Murray A; Tornling G
Article: ECLINICALMEDICINE. 2021;41:101152
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
Tornling G; Batta R; Porter JC; Williams B; Bengtsson T; Parmar K; Kashiva R; Hallberg A; Cohrt AK; Westergaard K; Dalsgaard C-J; Raud J
Article: ARTHRITIS & RHEUMATOLOGY. 2021;73(1):61-68
Respiratory Diseases as Risk Factors for Seropositive and Seronegative Rheumatoid Arthritis and in Relation to Smoking
Kronzer VL; Westerlind H; Alfredsson L; Crowson CS; Nyberg F; Tornling G; Klareskog L; Holmqvist M; Askling J
Article: INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH. 2018;91(3):285-291
Cancer incidence in Stockholm firefighters 1958-2012: an updated cohort study
Kullberg C; Andersson T; Gustavsson P; Selander J; Tornling G; Gustavsson A; Bigert C
Article: EUROPEAN RESPIRATORY JOURNAL. 2017;49(1):1600345
Differences in regional air trapping in current smokers with normal spirometry
Karimi R; Tornling G; Forsslund H; Mikko M; Wheelock AM; Nyren S; Skold CM
Article: DRUG DESIGN DEVELOPMENT AND THERAPY. 2016;10:2759-2770
Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
Kuna P; Bjermer L; Tornling G
Article: ARTHRITIS & RHEUMATOLOGY. 2015;67(11):2845-2854
Risk Factors for the Rapid Increase in Risk of Acute Coronary Events in Patients With New-Onset Rheumatoid Arthritis: A Nested Case-Control Study
Mantel A; Holmqvist M; Nyberg F; Tornling G; Frisell T; Alfredsson L; Askling J
Article: JOURNAL OF RHEUMATOLOGY. 2014;41(4):792-798
Reconciling Healthcare Professional and Patient Perspectives in the Development of Disease Activity and Response Criteria in Connective Tissue Disease-related Interstitial Lung Diseases
Saketkoo LA; Mittoo S; Frankel S; LeSage D; Sarver C; Phillips K; Strand V; Matteson EL
Article: RESPIRATORY RESEARCH. 2014;15(1):23
Lung density on high resolution computer tomography (HRCT) reflects degree of inflammation in smokers
Karimi R; Tornling G; Forsslund H; Mikko M; Wheelock AM; Nyren S; Skold CM
Article: BMJ OPEN. 2014;4(1):e004018
Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study
Ekstrom M; Gustafson T; Boman K; Nilsson K; Tornling G; Murgia N; Toren K
Article: PLOS ONE. 2012;7(8):e43644
Bronchoalveolar Lavage Results Are Independent of Season, Age, Gender and Collection Site
Olsen HH; Grunewald J; Tornling G; Skold CM; Eklund A
Article: PLOS ONE. 2012;7(3):e34232
Cell Recovery in Bronchoalveolar Lavage Fluid in Smokers Is Dependent on Cumulative Smoking History
Karimi R; Tornling G; Grunewald J; Eklund A; Skold CM
Article: RESPIRATORY RESEARCH. 2011;12(1):48
Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD
Lofdahl M; Kaarteenaho R; Lappi-Blanco E; Tornling G; Skold MC
Show more

All other publications

Corrigendum: WORLD ALLERGY ORGANIZATION JOURNAL. 2024;17(10):100973
Disease burden and unmet need for acute allergic reactions - A patient perspective"
Andersson E; Lofvendahl S; Olofsson S; Wahlberg K; Bjermer L; Tornling G; Janson C; Hjelmgren J
Conference publication: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2024;209:a1055
Buloxibutid, A Novel Angiotensin II Type 2 Receptor Agonist, Stabilized and Improved Lung Function in Individuals With Idiopathic Pulmonary Fibrosis in the 36-week Phase 2 AIR Trial
Ganslandt C; Maher TM; Molyneaux PL; Lindmark BE; Raud J; Tornling G; Bengtsson T; Rosendahl E
Conference publication: VALUE IN HEALTH. 2023;26(12):S200-S201
USING DISCRETE CHOICE EXPERIMENT TO ELICIT TREATMENT PREFERENCES FOR ACUTE ALLERGIC REACTIONS IN SWEDEN: THE CASE OF PATIENTS WITH SWALLOWING PROBLEMS
Lofvendahl S; Andersson E; Tornling G; Olofsson S; Hjelmgren J
Conference publication: 2023;:pa3501
An open-label, pharmacodynamic trial investigating vascular effects of the angiotensin II type 2 receptor (AT2R) agonist (ATRAG) C21
Ganslandt C; Rein-Hedin E; Sjöberg F; Tornling G; Bengtsson T; Overbeck K; Rosendahl E; Batta R; Bjerring B; Raud J; Dalsgaard C-J
Conference publication: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2023;207(Supplement_1):a6480
Development of Angiotensin II Type 2 Receptor Agonists 'ATRAGs' for Treatment of Pulmonary Fibrosis and Pulmonary Hypertension
Batta R; Raud J; Tornling G; Nygard M; Dalsgaard C-J
Conference publication: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2023;207(Supplement_1):a2531
An Updated Interim Analysis of the Air Trial; an Open-label, Single-arm, 36-week, Phase 2 Trial of an Angiotensin Type 2 Receptor Agonist, C21, in Individuals with IPF
Batta R; Maher TM; Ganslandt C; Tornling G; Bengtsson T; Pophale H; Rosendahl E
Conference publication: EUROPEAN HEART JOURNAL. 2022;43:3044
Investigation of the effect of the angiotensin II type 2 receptor (AT2R) agonist C21 on plasma NT-proBNP, a diagnostic biomarker, in subjects hospitalised with COVID-19
Batta R; Tornling G; Rosendahl E; Bengtsson T; Raud J
Conference publication: 2022;:4402
Interim results from AIR, an open-label, single arm, 36-week ph 2 trial of C21 in subjects with idiopathic pulmonary fibrosis
Maher T; Ganslandt C; Batta R; Tornling G; Bengtsson T; Pophale H; Rosendahl E; Maher T
Conference publication: 2022;:1051
Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of the angiotensin II type 2 receptor agonist C21 on lung pathology in subjects previously hospitalised with COVID-19
Batta R; Tornling G; Bengtsson T; Devaraj A; Kashiva R; Rajkondawar A; Parmar K; Bhalani N; Bohra A; Cohrt A; Ganslandt C
Conference publication: RHEUMATOLOGY. 2022;61
A PHASE 2 RANDOMISED PLACEBO-CONTROLLED TRIAL INVESTIGATING THE EFFECT OF THE ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST C21 ON COLD-INDUCED VASOCONSTRICTION IN PATIENTS WITH RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
Herrick AL; Batta R; Overbeck K; Raud J; Manning J; Dinsdale G; Murray A; Tornling G
Preprint: MEDRXIV. 2021
The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 - a double-blind, randomized, placebo-controlled Phase 2 trial
Tornling G; Batta R; Porter J; Bengtsson T; Parmar K; Kashiva R; Hallberg A; Cohrt AK; Westergaard K; Dalsgaard C-J; Raud J
Preprint: SSRN ELECTRONIC JOURNAL. 2021
Seven Days Treatment With the Angiotensin II Type 2 Receptor Agonist C21 in Hospitalized COVID-19 Patients: A Placebo-Controlled Randomized Phase 2 Trial
Tornling G; Batta R; Porter JC; Williams B; Bengtsson T; Parmar K; Kashiva R; Hallberg A; Cohrt AK; Westergaard K; Dalsgaard C-J; Raud J
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020;22(1):E225-225
Pathological Insight into 5-HT_2B Receptor Activation in Fibrosing Interstitial Lung Diseases
Lofdahl A; Tornling G; Wigen J; Larsson-Callerfelt A-K; Wenglen C; Westergren-Thorsson G
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2020;79:1099
INHIBITION OF MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES-1) BY GS-248 REDUCES PROSTAGLANDIN E2 BIOSYNTHESIS WHILE INCREASING PROSTACYCLIN IN HUMAN SUBJECTS
Edenius C; Ekstrom G; Kolmert J; Morgenstern R; Stenberg P; Jakobsson PJ; Tornling G
Letter: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2016;194(1):118-120
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma
Brightling CE; Nordenmark LH; Jain M; Piper E; She D; Braddock M; Colice G; Tornling G
Meeting abstract: ANNALS OF THE RHEUMATIC DISEASES. 2014;73:632
WHAT DRIVES THE RAPID INCREASE IN RISK OF ACUTE CORONARY SYNDROME FOLLOWING RA DIAGNOSIS?
Mantel A; Holmqvist M; Nyberg F; Tornling G; Frisell T; Alfredsson L; Askling J
Review: SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. 2007;28(4):451-458
Pulmonary complications of polymyositis and dermatomyositis
Fathi M; Lundberg IE; Tornling G
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2006;54(9):S659
Longitudinal evaluation of interstitial lung disease in polymyositis and dermatomyositis.
Lundberg IE; Fathi M; Vikgren J; Boijsen M; Tylen U; Jorfeldt L; Tornling G
Meeting abstract: VALUE IN HEALTH. 2003;6(6):611
Asthma treatment preference study -: A conjoint analysis of preferred drug treatments
Berggren F; Ställberg B; Tornling G; Fält K; Andersson S; Karlsson G; Johansson G

Employments

Professor Emeritus, Department of Medicine, Karolinska Institutet, 2024-2027
Adjunct Professor, Department of Medicine, Karolinska Institutet, 2011-2013
Adjunct Professor, Department of Medicine, Karolinska Institutet, 2008-2010

Articles

All other publications

Employments

News from KI

Events from KI